Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.36 USD | 0.00% | 0.00% | +27.01% |
Financials (USD)
Sales 2024 * | 194M | Sales 2025 * | 232M | Capitalization | 312M |
---|---|---|---|---|---|
Net income 2024 * | -3M | Net income 2025 * | -19M | EV / Sales 2024 * | 0.63 x |
Net cash position 2024 * | 189M | Net Debt 2025 * | 65.1M | EV / Sales 2025 * | 1.62 x |
P/E ratio 2024 * |
-89.3
x | P/E ratio 2025 * |
-16.2
x | Employees | 203 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.01% |
Latest transcript on Vanda Pharmaceuticals Inc.
Current month | +12.61% | ||
1 month | +32.02% | ||
3 months | +22.65% | ||
6 months | +50.99% | ||
Current year | +27.01% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 02-10-31 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 12-11-30 |
Scott Howell
HRO | Human Resources Officer | - | 19-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard W. Dugan
BRD | Director/Board Member | 82 | 05-11-30 |
Chief Executive Officer | 64 | 02-10-31 | |
Director/Board Member | 72 | 20-02-13 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.34% | 28 M€ | -0.20% | ||
0.22% | 25 M€ | -1.16% | - | |
0.05% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 5.36 | +4.48% | 908 363 |
24-05-14 | 5.13 | +1.58% | 774,501 |
24-05-13 | 5.05 | +0.20% | 833,009 |
24-05-10 | 5.04 | +0.60% | 1,384,022 |
24-05-09 | 5.01 | -6.53% | 1,969,904 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.01% | 312M | |
+7.52% | 113B | |
+11.38% | 106B | |
+1.14% | 22.27B | |
-12.64% | 22.22B | |
-5.52% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- VNDA Stock